Yes. As I said in my remarks, even if this post-marketing surveillance network were to be well funded, one would still need to make decisions about where one is going to concentrate. I would concentrate on areas that, on the basis of initial information from randomized trials, give concern over possible side effects. I think I'd concentrate on diseases for which drugs are used frequently, such as depression or heart failure. I think you really would need a group of practitioners, regulators, researchers, and policy-makers to sit down and prioritize. For sure, it can't be a holus-bolus thing; we wouldn't get anywhere.
On April 8th, 2008. See this statement in context.